UK markets closed

Scancell Holdings plc (SCLP.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
11.77+0.27 (+2.35%)
At close: 4:19PM GMT

Scancell Holdings plc

John Eccles House
Robert Robinson Avenue Oxford Science Park
Oxford OX4 4GP
United Kingdom
44 1865 338 069
http://www.scancell.co.uk

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees22

Key executives

NameTitlePayExercisedYear born
Dr. Clifford HollowayCEO & Director290.44kN/AN/A
Prof. Lindy Gillian DurrantChief Scientific Officer & Director201.25kN/AN/A
Dr. Sally Elizabeth AdamsDevel. Director & Director213.72kN/A1961
Mr. Keith GreenDirector of Fin. & Admin.N/AN/AN/A
Dr. Samantha PastonHead of ResearchN/AN/AN/A
Dr. Adrian ParryHead of ManufacturingN/AN/AN/A
Dr. Gillies O'Bryan-TearChief Medical OfficerN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in GBp.

Description

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 that is in phase I/II combination trials for the treatment of non-small cell lung cancer; and Modi-1, which is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2 that is in pre-clinical trial for the treatment of multiple solid tumors. The company has a research collaboration agreement with BioNTech to develop T-cell receptor based therapeutics; licensing and collaboration agreement with ISA Pharmaceuticals B.V. to use ISA's AMPLIVANT adjuvant technology for the development and commercialization of Modi-1; and collaboration agreements with Cobra Biologics, Centre for Research on Global Virus Infections, the University of Nottingham, and the Nottingham Trent University to develop a vaccine for COVID-19. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Corporate governance

Scancell Holdings plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.